Skip to main content

Stephnie A. John

Associate

[email protected]

+1.212.692.6257

Share:

Stephnie focuses her practice on advising clients across the health care industry on regulatory, transactional, and compliance matters. She serves as regulatory counsel to private equity firms and other investors in transactions involving a range of health care targets, including health care systems and other health care providers, PBMs, pharmacies, nurse staffing companies, and laboratories. She regularly advises pharmacies, PBMs, third party payors, digital health companies, value-based contracting entities, and care providers on regulatory matters. With her previous experience at a state Medicaid agency and the Medicare Appeals Council, she is able to strategically advise clients on regulatory and compliance issues relating to Medicare and Medicaid.

Prior to joining Mintz, Stephnie was an attorney advisor at the Office of General Counsel of the DC Department of Health Care Finance. Stephnie provided DC’s Medicaid agency with legal and compliance counsel and defended it in administrative proceedings, including provider appeals of Medicaid payment suspensions based on allegations of fraud and pharmacy overpayment recoupments identified by state Medicaid audit. During the COVID-19 pandemic, Stephnie helped to ensure the agency’s compliance with the CARES Act. Earlier, Stephnie was an associate at Healthcare Legal Solutions, LLC, where she reviewed hospital and health care providers’ medical claims and billing practices, drafted administrative appeals on behalf of providers, and strategized with clients to ensure compliance with Medicare and Medicaid regulations and reduce payment denials.

While attending George Washington University School of Law, Stephnie was managing editor of the Federal Circuit Bar Journal. She also served as a legal extern for the Medicare Appeals Council, housed under the Departmental Appeals Board at the Department of Health and Human Services, and clerked for two law firms in the Washington metropolitan area.

Not admitted to practice law in New York.  Admitted to practice only in the District of Columbia.

viewpoints

Read about the impact of changes to Medicare Part D’s Part D benefit redesign and other changes that went into effect on January 1, 2025, and additional changes to watch for in 2025.

Read more

Mintz’s Pharmacy Benefits and PBM Contracting Practice is pleased to present the ‘Fourth Edition: Q1 2025’ of our Mintz IRA Update, a regular publication that delves into developments of the Inflation Reduction Act of 2022 (IRA) and their impact on pharmaceutical supply chain stakeholders.

Read more

Effective immediately, on August 22, 2024, the Office of Health Care Affordability (OHCA) adopted revisions to the cost and market impact review (CMIR) regulations (Revised Regulations), which govern California’s pre-closing health care transaction review process. As discussed in our prior post, certain health care entities must provide OHCA with notice of a transaction at least 90 days prior to closing. The Revised Regulations, among other things: (1) expand who must file a notice; (2) narrow the applicability of the health care professional shortage area threshold; (3) clarify calculation of California-derived revenue; (4) clarify confidentiality of expedited review request documents; and (5) add a required attestation.

Read more

In ‘Third Edition: Q2 2024’ of the Mintz IRA Update, we cover updates to the Medicare Drug Price Negotiation Program being considered by CMS, developments in litigation challenging the program, the consequences and costs of redesigning the Part D program, opposition to the use of march-in rights to lower drug prices, and the growing use of state prescription drug affordability boards.

Read more
Read about criticism of the Biden administration’s proposal exploring the use of “march-in rights” granted under the Bayh-Doyle Act (the Act) to seize pharmaceutical patents if the administration believes that a pharmaceutical product is not available to the public at a reasonable price.

Read more
Read about updates to the Medicare Drug Price Negotiation Program being considered by CMS, including changes to the 2027 negotiation process, plus industry response to draft guidance and drug makers’ softened perspective on the IRA’s impact.
Read more
Read less

News & Press

Press Release Thumbnail Mintz

A Mintz team led by Richard Gervase, Member and Chair of the firm’s Royalty & Revenue Interest Financing Transactions Group, advised global investment firm Sixth Street in a non-dilutive, senior secured credit facility of up to $475 million for Apellis Pharmaceuticals. Apellis received $375 million in funding at close, with ability to access an additional $100 million under the facility at the Company’s option prior to September 2025, subject to the satisfaction of certain conditions.

Read less

Recognition & Awards

  • Summer Public Interest Fellow, South Asian Bar Association (2015)

Read less

Involvement

  • Legal Counsel, Dil to Dil, a nonprofit organization dedicated to South Asian mental health advocacy
  • Member, American Health Law Association
Read less